Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Vaccine

Volumn 33, Issue 36, 2015, Pages 4437-4445

  Nolan, Terry ^a   O'Ryan, Miguel ^b   Wassil, James ^c,e   Abitbol, Véronique ^d   Dull, Peter ^c,f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF CHILE   (Chile)

^c Novartis Vaccines and Diagnostics Inc   (United States)

^d Novartis Vaccines and Diagnostics Inc   (France)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

^f PFIZER INC   (United States)

Author keywords

Adolescents; Meningitis; Meningococcal B vaccine; Outbreak; Prevention; University

Indexed keywords

MEMBRANE ANTIGEN; MENINGOCOCCAL B VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; 4CMENB VACCINE; BACTERIUM ANTIBODY;

ADOLESCENT; ADULT; CANADA; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG SAFETY; ENDEMIC DISEASE; EXPERIENCE; HUMAN; IMMUNOGENICITY; LICENSING; MENINGOCOCCOSIS; META ANALYSIS (TOPIC); NASOPHARYNX; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); VACCINATION; YOUNG ADULT; BLOOD; HEALTH; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; SERUM BACTERICIDAL ACTIVITY;

ADOLESCENT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; GLOBAL HEALTH; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; YOUNG ADULT;

EID: 84939571917     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.011     Document Type: Review

References (68)

1. Jafri R., Ali A., Messonnier N., Tevi-Benissan C., Durrheim D., Eskola J., et al. Global epidemiology of invasive meningococcal disease. Popul Health Metics 2013, 11:17.
2. Rouphael N., Stephens D. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol 2012, 799:1-20.
3. Rosenstein N., Perkins B., Stephens D., Popovic T., Hughes J. Meningococcal disease. N Engl J Med 2001, 344:1378-1388.
4. European Centre for Disease Prevention and Control Surveillance of invasive bacterial diseases in Europe 2008/2009 2011, ECDC, Sotckholm.
5. Harrison L., Trotter C., Ramsay M. Global epidemiology of meningococcal disease. Vaccine 2009, 27S:B51-B63.
6. Martin D., McDowell R. The epidemiology of meningococcal disease in New Zealand in 2003. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research (ESR) 2004, Ministry of Health, Wellington.
7. Baker M., Martin D., Kieft C., Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001, 37:S13-S19.
8. Guidelines for the early clinical and public health management of meningococcal disease in Australia. Revised Edition 2007. Communicable Diseases Network Australia: Commonwealth Department of Health and Ageing 2007.
9. World Health Organization (WHO) Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011, 86(47):521-539.
10. Christensen H., May M., Bowen L., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(12):853-861.
11. Delbos V., Lemée L., Bénichou J., Berthelot G., Taha M., Caron F. Meningococcal carriage during a clonal meningococcal B outbreak in France. Eur J Clin Microbiol Infect Dis 2013, 32:1451-1459. B14 STOP study group.
12. MacLennan J., Kafatos G., Neal K., Andrews N., Cameron C., Roberts R., et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006, 12(6):950-957.
13. Broderick M., Faix D., Hansen C., Blair P. Trends in meningococcal disease in the United States military, 1971-2010. Emerging Infect Dis 2012, 18(9):1430-1437.
14. Sáfadi M.A., Espinosa de los Monteros L.E., López E., Sàez-Llorens X., Lemos A.P., Moreno-Espinosa S., et al. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative. Expert Rev Vaccines 2013, 12(8):903-915.
15. Inés Agudelo C., Sanabria O.M., Ovalle M.V. Serogroup Y meningococcal disease, Columbia. Emerg Infect Dis 2008, 15(6):990-991.
16. Nieto-Guevara J., Luciani K., Montesdeoca-Melían A., Mateos-Durán M. Epidemiology of meningococcal disease in the Panamanian pediatric population, 1998-2008. J Infect Dev Ctries 2011, 5(5):318-323.
17. Abad R., Agudelo C.I., Brandileone M.C., Chanto G., Gabastou J.M., Hormazabal J.C., et al. Molecular characterization of invasive serogroup Y Neisseria meningitidis strains isolated in the Latin America region. J Infect 2009, 59(2):104-114.
18. Gilca R., Deceuninck G., Lefebvre B., Tsang R., Amini R., Gilca V., et al. The changing epidemiology of meningococcal disease in Québec, Canada, 1991-2011: potential implications of emergence of new strains. PLoS ONE 2012, 7(11):e50659.
19. Diermayer M., Hedberg K., Hoesly F., Fischer M., Perkins B., Reeves M., Fleming D. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999, 281(16):1493-1497.
20. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002, 51(9):717-722.
21. Campbell H., Borrow R., Salisbury D., Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009, 27(2):B20-B29.
22. de Greeff S., de Melker H., Spanjaard L., Schouls L., van DerEnde A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatric Infect Dis J 2006, 25(1):79-80.
23. Sierra G., Campa H., Varcacel N., Garcia I., Izquierdo P., Sotolongo P., et al. Vaccine against group B Neiserria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14(2):208-210. discussion 195-207.
24. Pérez Rodríguez A., Dickinson F., Baly A., Martinez R. Epidemiological impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz, Rio de Janeiro 1999, 94(4):433-440.
25. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZBTM: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
26. Kelly C., Arnold R., Galloway Y., O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007, 166:817-823.
27. Centers for Disease Control and Prevention National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR 2012, 61:671-677.
28. Nelson J., Bittner R., Bounds L., Zhao S., Baggs J., Donahue J., et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health 2009, 99(S2):S389-S397.
29. Dorella C.G., Stokley S., Yankeya D., Markowitzc L.E. Compliance with recommended dosing intervals for HPV vaccination among females, 13-17 years, National Immunization Survey-Teen, 2008-2009. Vaccine 2012, 30(3):503-505.
30. Bjune G., Hoiby E., Gronnesby J., Arnesen O., Fredriksen J.H., Lindbak A.K., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338:1093-1096.
31. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-B12.
32. O'Hallahan J., McNicholas A., Galloway Y., O'Leary E., Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009, 122:48-59.
33. Giuliani M., Adu-Boble J., Comanducci M., Aricò B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103:10834-10839.
34. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010, 107(45):19490-19495.
35. Wang X., Cohn A., Comanducci M., Andrew L., Zhao X., MacNeil J.R., et al. Prevalence and genetic diversity of candidate vaccine antigens against invasive Neisseria meningitidis isolates in the United States. Vaccine 2011, 29:4739-4744.
36. Hong E., Giuliani M., Deghmane A., Comanducci M., Brunelli B., Dull P., et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?. Vaccine 2013, 31:1113-1116.
37. Kimura A., Toneatto D., Kleinschmidt A., Wang H., Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin vaccine Immunol 2011, 18(3):483-486.
38. Toneatto D., Ismaili S., Ypma E., Vienken K., Oster P., Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011, 7:646-653.
39. Santolaya M., O'Ryan M., Valenzuela M., Prado V., Vergara R., Muñoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379(9816):614-624.
40. Read R., Baxter D., Chadwick D., Faust S., Finn A., Gordon S., et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014, 384:2123-2131.
41. Protocol Immunization Québec (PIQ) Edition 6. Publication No. 13-283-06E 2014, Available at: http://msssa4.msss.gouv.qc.ca/fr/document/publication.nsf/4b1768b3f849519c852568fd0061480d/6335dde40226af59852575cc0048804d.
42. Institut national de santé publique du Québec (INSPQ). Rapport interimaire de surveillance de la securite de la premiere dose du vaccin contre le meningocoque de serogroupe B au Saguenay-Lac-Saint-Jean 2015, Available at: http://santesaglac.com/medias/Vaccination_mening_B/ResumeExecutif_INSPQ.pdf.
43. Perrett K., McVernon J., Richmond P., Marshall H., Nissen M., August A., et al. Kinetics of the immune response to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents. Submission under review in Vaccine as of December 2014.
44. Findlow J., Bai X., Findlow H., Newton E., Kaczmarski E., Borrow R. Safety and immunogenicity of a four component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group A, C, W135 and Y conjugate vaccine (Menveo) in UK laboratory workers with potential occupational exposure to meningococci. Presented at: 18th International Pathogenic Neisseria Conference (IPNC) Meeting 2012, Poster available at: http://neisseria.org/ipnc/2012/IPNC_2012_abstracts.pdf.
45. Patel M. Outbreak of serogroup B meningococcal disease on university campuses - 2013. Meningitis and Vaccine Preventable Diseases Branch, CDC. Presented at: ACIP February 2014 Meeting 2014, Available at: http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2014-02.pdf [accessed 15.11.14].
46. Su E.L., Snape M. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines 2011, 10(5):575-588.
47. Dull P., Bai X., Bazaz R., Nolan K., Nazir A., Karsten A., et al. Bactericidal antibody levels following quadrivalent conjugate (MenACWY-CRM) or serogroup B (4CMenB) meningococcal vaccines in a phase 3 study to evaluate the effect of vaccination on pharyngeal carriage of N. Meningitidis in young adults. Presented at: MRF 2013 2013, Available at: http://www.meningitis.org/assets/x/55520.
48. Santolaya M., O'Ryan M., Valenzuela M., Prado V., Vergara R., Muñoz A., et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccines Immunother 2013, 9(11):2304-2310.
49. Vogel U., Taha M.K., Vazquez J.A., Findlow J., Claus H., Stefanelli P., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013, 13:416-425.
50. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Aricò B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
51. Frosi G., Biolchi A., Lo Sapio M., Rigat F., Gilchrist S., Lucidarme J., et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013, 31(43):4968-4974.
52. Lemos A.P., Gorla M.C., Brandileone M.C., Orlandi L., Rigat F., Boccadifuoco G., et al. MATS based coverage prediction for the 4CMenB vaccine on Neisseria meningitides B (MenB) Brazilian invasive strains. Poster presented at: 18th International Pathogenic Neisseria Conference (IPNC) Meeting 2012, Available at: http://neisseria.org/ipnc/2012/IPNC_2012_abstracts.pdf.
53. Nissen M., Tozer S.J., Whiley D., Smith H., Rockett R., Jennison A., et al. Use of the Meningococcal Antigen Typing System (MATS) to assess the Australian meningococcal strain coverage with a multicomponent serogroup B vaccine. XVIIIth International Pathogenic Neisseria conference 2012, Available at: http://neisseria.org/ipnc/2012/IPNC_2012_abstracts.pdf [accessed 02.02.15].
54. Bettinger J., Scheifele D., Halperin S., Vaudry W., Findlow J., Borrow R., et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CmenB). Vaccine 2014, 32(2014):124-130.
55. Křížová P., Musílek M., Vacková Z., Kozáková J., Claus H., Vogel U., et al. Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic. Epidemiol Mikrobiol Imunol 2014, 63(2):103-106.
56. Tzanakaki G., Hong E., Kesanopoulos K., Xirogianni A., Bambini S., Orlandi L., et al. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol 2014, 14:111.
57. Kim E., Paulos S., Carlone G., Plikaytis B., Cohn A. Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in the United States. Presented at: 18th International Pathogenic Neisseria Conference (IPNC) Meeting 2012, Available at: http://neisseria.org/ipnc/2012/IPNC_2012_abstracts.pdf.
58. Cohn A. Serogroup B meningococcal outbreaks and control. Meningitis and Vaccine Preventable Diseases Branch, CDC. Presented at: Current Issues in Immunization NetConferences 2014, Available at: http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2014-02.pdf [accessed 15.01.15].
59. Centers for Disease Control and Prevention. Serogroup B meningococcal vaccine & outbreaks. Available at: [accessed 15.01.15]. http://www.cdc.gov/meningococcal/outbreaks/vaccine-serogroupb.html.
60. Centers for Disease Control and Prevention Emergency Preparedness and Response. Notice to Healthcare providers: recognizing and reporting serogroup B meningococcal disease associated with outbreaks at Princeton University and the University of California at Santa Barbara 2013, Available at: http://emergency.cdc.gov/han/han00357.asp [accessed 15.01.15].
61. Centers for Disease Control and Prevention CDC Newsroom. Meningococcal Disease Update 2014, Available at: http://www.cdc.gov/media/releases/2014/s0318-meningococcal-diisease.html [accessed 15.01.15].
62. De Wals P., Nguyen V.H., Erickson L., Guay M., Drapeau J., St-Laurent J. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004, (22):1233-1240.
63. Unwin B., Goodie J., Reamy B., Quinlan J. Care of the college student. Am J Fam Physician 2013, 88(9):596-604.
64. The National Foundation for Infectious Diseases Bridging from a strong childhood foundation to a healthy adulthood. A report on strategies to increase adolescent immunization rates. NFID 2005, Available at: https://www2.aap.org/immunization/pediatricians/pdf/ImmunizationofAdolescents_nfid.pdf.
65. Snape M., Saroey P., John T., Robinson H., Kelly S., Grossger N., et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ 2013, 185(15):E715-E724.
66. Vesikari T., Esposito S., Prymula R., Ypma E., Kohl I., Toneatto D., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381(9869):825-835.
67. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307(6):573-582.
68. Snape M.D., Dawson T., Oster P., Evans A., John T., Ohene-Kena B., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29(11):e71-e79.